Comparison of efficacy of recombinant human interleukin-11 and herombopag olamine tablets on chemotherapy-induced thrombocytopenia in breast cancer

doi:10.11958/20241463

Abstract

Abstract:

Objective To compare the efficacy of recombinant human interleukin-11 (rhIL-11) and herombopag olamine tablets on chemotherapy-induced thrombocytopenia (CIT) in breast cancer. Methods Eighty-six prospectively selected breast cancer patients with CIT were randomly divided into the control group (administered rhIL-11) and the study group (administered herombopag olamine tablets), with 43 cases in each group. Before treatment and 14 days after treatment, platelet parameters [platelet count (PLT), plateletcrit (PCT), platelet distribution width (PDW) and mean platelet volume (MPV)] and flow cytometry were measured by automated hematology analyzer. Cellular immune indicators (CD3⁺, CD4⁺, CD8⁺and CD4⁺/CD8⁺) were detected by flow cytometer. Enzyme-linked immunosorbent assay was used to determine the levels of thrombopoietin (TPO) and interleukin-11 (IL-11). The above parameters were compared between the two groups, and the incidence of adverse reactions in the two groups was recorded. Results After treatment, PLT, PCT, CD3⁺, CD4⁺, CD4⁺/CD8⁺, TPO and IL-11 in both groups were higher than before treatment, and which was higher in the study group than the control group (P<0.05). After treatment, PDW, MPV and CD8⁺of both groups were lower than before treatment, and the study group was lower than the control group (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion Both rhIL-11 and herombopag olamine tablets are effective in treating breast cancer with CIT. Compared with rhIL-11, herombopag olamine tablets have more advantages in improving platelet parameters, cellular immune indicators, TPO and IL-11, and do not increase the adverse reactions.

Key words: interleukin-11, ethanolamine, thrombocytopenia, breast neoplasms, herombopag olamine tablets

CLC Number:

R969.4

Figures/Tables 4

References 20

[1]	陈芷彦, 伍秋苑, 邓裕华, 等. 类器官技术在乳腺癌研究中的现状及应用[J]. 天津医药, 2024, 52(6):668-672.
	CHEN Z Y, WU Q Y, DENG Y H, et al. Status and application of organoid technology in breast cancer research[J]. Tianjin Med J, 2024, 52(6):668-672. doi:10.11958/20231745.
[2]	中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组,邵志敏. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志, 2023, 33(12):1092-1186.
	Breast Cancer Professional Committee of China Anti Cancer Association,Breast Oncology Group, Oncology Branch,Chinese Medical Association,SHAO Z M. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association(2024 edition)[J]. China Oncol, 2023, 33(12):1092-1186. doi:10.19401/j.cnki.1007-3639.2023.12.004.
[3]	中华医学会肿瘤学分会肿瘤支持康复治疗学组. 肿瘤治疗相关血小板减少症的临床管理专家共识[J]. 肿瘤, 2021, 41(12):812-827.
	Tumor Support Rehabilitation Therapy Group of the Oncology Branch of the Chinese Medical Association. Consensus on clinical management of cancer therapy-related thrombocytopenia[J]. Tumor, 2021, 41(12):812-827. doi:10.3781/j.issn.1000-7431.2021.2111-0882.
[4]	中国临床肿瘤学会肿瘤化疗所致血小板减少症共识专家委员会. 肿瘤化疗所致血小板减少症诊疗中国专家共识(2018版)[J]. 中华肿瘤杂志, 2018, 40(9):714-720.
	Consensus Expert Committee on Thrombocytopenia Caused by Tumor Chemotherapy of the Chinese Society of Clinical Oncology. Consensus on clinical diagnosis,treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)[J]. Chin J Oncol, 2018, 40(9):714-720. doi:10.3760/cma.j.issn.0253-3766.2018.09.014.
[5]	常丽, 孙素芹, 任宏, 等. 重组人白细胞介素-11对恶性实体瘤患者化疗所致血小板减少症一级预防的有效性和安全性[J]. 癌症进展, 2023, 21(24):2710-2714.
	CHANG L, SUN S Q, REN H, et al. Efficacy and safety of recombinant human interleukin-11 in primary prevention of chemotherapy-induced thrombocytopenia in patients with malignant solid tumors[J]. Oncology Progress, 2023, 21(24):2710-2714. doi:10.11877/j.issn.1672-1535.2023.21.24.11.
[6]	中国临床肿瘤学会抗淋巴瘤联盟, 中国临床肿瘤学会抗白血病联盟, 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, 等. 重组人白介素-11防治血小板减少症临床应用中国专家共识(2021年版)[J]. 临床肿瘤学杂志, 2020, 25(12):1129-1137.
	Chinese Society of Clinical Oncology Anti Lymphoma Alliance,Chinese Society of Clinical Oncology Anti Leukemia Alliance, Expert Committee on Safety Management of Antitumor Drugs of the Chinese Society of Clinical Oncology, et al. Chinese expert consensus on the clinical application of recombinant human interleukin-11 in the prevention and treatment of thrombocytopenia (2021 Edition)[J]. Chin Clin Oncol, 2020, 25(12):1129-1137. doi:10.3969/j.issn.1009-0460.2020.12.014.
[7]	中国临床肿瘤学会(CSCO)抗肿瘤药物治疗安全管理专家委员会. 海曲泊帕临床应用指导原则[J]. 白血病·淋巴瘤, 2022, 31(10):577-582.
	Chinese Society of Clinical Oncology (CSCO) Expert Committee on Safety Management of Antitumor Drug Therapy. Guiding principles for clinical application of hetrombopag[J]. Journal of Leukemia and Lymphoma, 2022, 31(10):577-582. doi:10.3760/cma.j.cn115356-20220809-00229.
[8]	郁飞文, 彭猛青, 张茹茹, 等. 海曲泊帕乙醇胺片对抗肿瘤治疗后血小板减少症患者临床疗效及对血清TPO、STAT3、MAPK的影响[J]. 药物评价研究, 2023, 46(3):614-620.
	YU F W, PENG M Q, ZHANG R R, et al. Clinical efficacy and effect of Herombopag Olamine Tablets on serum TPO,STAT3 and MAPK in patients with thrombocytopenia after anti-tumor therapy[J]. Drug Eval Res, 2023, 46(3):614-620. doi:10.7501/j.issn.1674-6376.2023.03.020.
[9]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10):954-1040.
	Breast Cancer Professional Committee of China Anti Cancer Association. Guidelines and specifications for breast cancer diagnosis and treatment of China Anti Cancer Association (2021)[J]. China Oncol, 2021, 31(10):954-1040. doi:10.19401/j.cnki.1007-3639.2021.10.013.
[10]	中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]. 中国肿瘤临床, 2019, 46(18):923-929.
	Cancer Clinical Chemotherapy Professional Committee of China Anti Cancer Association,Cancer Support Therapy Professional Committee of China Anti Cancer Association. Consensus on the clinical diagnosis,treatment,and prevention of chemotherapy-in-duced thrombocytopenia in China (2019 version)[J]. Chin J Clin Oncol, 2019, 46(18):923-929. doi:10.3969/j.issn.1000-8179.2019.18.914.
[11]	客蕊, 张旭明, 迟庆滨. 中医药防治恶性肿瘤化疗后血小板减少症的研究进展[J]. 江苏中医药, 2021, 53(9):77-81.
	KE R, ZHANG X M, CHI Q B. Research progress on traditional Chinese medicine in the prevention and treatment of thrombocytopenia after chemotherapy for malignant tumors[J]. Jiangsu J Tradit Chin Med, 2021, 53(9):77-81. doi:10.19844/j.cnki.1672-397X.2021.09.026.
[12]	中华中医药学会血液病分会, 中国中西医结合学会肿瘤专业委员会, 北京中西医结合学会肿瘤专业委员会. 肿瘤化疗相关性血小板减少症中医药防治专家共识[J]. 北京中医药, 2021, 40(5):451-455.
	Hematology Branch of the Chinese Society of Traditional Chinese Medicine,Cancer Professional Committee of the Chinese Society of Integrated Traditional Chinese and Western Medicine, Cancer Professional Committee of Beijing Association of Traditional Chinese and Western Medicine. Expert consensus on traditional Chinese medicine prevention and treatment of tumor chemotherapy associated thrombocytopenia[J]. Beijing J Tradit Chin Med, 2021, 40(5):451-455. doi:10.16025/j.1674-1307.2021.05.002.
[13]	卫紫钰, 秦悦莹, 郭炎, 等. 肿瘤化疗相关性血小板减少症(CIT)药物治疗新进展[J]. 山东化工, 2023, 52(1):88-90.
	WEI Z Y, QIN Y Y, GUO Y, et al. New progress in drug therapy of tumor chemotherapy-associated thrombocytopenia(CIT)[J]. Shandong Chemical Industry, 2023, 52(1):88-90. doi:10.3969/j.issn.1008-021X.2023.01.025.
[14]	范海艳, 刘怡雯. 重组人血小板生成素、重组人白介素-11预防卵巢癌化疗患者血小板减少症的对比研究[J]. 药品评价, 2023, 20(2):237-240.
	FAN H Y, LIU Y W. Comparative study of recombinant human thrombopoietin and recombinant human interleukin-11 in preventing thrombocytopenia in patients with ovarian cancer undergoing chemotherapy[J]. Drug Eval, 2023, 20(2):237-240. doi:10.19939/j.cnki.1672-2809.2023.02.29.
[15]	王君萍, 黄玲玲, 张梅, 等. 海曲泊帕合理应用评价标准的建立与应用[J]. 中国医院用药评价与分析, 2023, 23(9):1127-1130.
	WANG J P, HUANG L L, ZHANG M, et al. Establishment and application of evaluation criteria for rational use of hetrombopag[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2023, 23(9):1127-1130. doi:10.14009/j.issn.1672-2124.2023.09.020.
[16]	刘丹娜, 苏田丽, 吴通, 等. 基于文献分析药学监护对化疗相关性血小板减少症的作用及流程[J]. 中国药师, 2022, 25(7):1235-1239.
	LIU D N, SU T L, WU T, et al. Effects and procedures of pharmaceutical care in chemotherapy-induced thrombocytopenia based on lit-erature analysis[J]. Frontiers in Pharmaceutical Sciences, 2022, 25(7):1235-1239. doi:10.19962/j.cnki.issn1008-049X.2022.07.024.
[17]	莫峥, 于飞, 李利红, 等. 海曲泊帕治疗实体瘤化疗所致血小板减少症效果观察[J]. 肿瘤研究与临床, 2023, 35(9):703-705.
	MO Z, YU F, LI L H, et al. Efficacy observation of hetrombopag in treatment of chemotherapy-induced thrombocytopenia in solid tumors[J]. Cancer Research and Clinic, 2023, 35(9):703-705. doi:10.3760/cma.j.cn115355-20230324-00149.
[18]	宋雪雯. 第第一部分:促血小板生成素受体激动剂对慢性难治性ITP患者免疫稳态的调节及其临床预测价值;第二部分:中国血友病真实世界研究:一项天津市单中心研究[D]. 中国医学科学院北京协和医学院, 2020.
	SONG X W. Part One:Effect of thrombopoietin receptor agonists on regulation of immune homeostasis and its clinical predictive value in patients with chronic refractory ITP; Part Two:Real-world analysis of hemophilia patients in China:A single center's experience[D]. Peking Union Medical College, Chinese Academy of Medical Sciences, 2020. doi:10.27648/d.cnki.gzxhu.2020.000006.
[19]	杨凌妍, 刘秀梅, 沈曦凤, 等. 重组人白细胞介素-11药物利用评价标准建立与使用合理性分析[J]. 中国药物与临床, 2023, 23(3):143-149.
	YANG L Y, LIU X M, SHEN X F, et al. Establishment and rationality analysis of evaluation criteria for drug utilization of recombinant human interleukin-11[J]. Chin Remed & Clin, 2023, 23(3):143-149. doi:10.11655/zgywylc2023.03.002.
[20]	庞丽娜, 龚帅, 张胜利, 等. 海曲泊帕治疗恶性肿瘤化疗相关血小板减少的效果和安全性[J]. 河南医学研究, 2023, 32(22):4048-4051.
	PANG L N, GONG S, ZHANG S L, et al. Hetrombopag's efficacy and security in the treatment of thrombocytopenia by chemotherapy[J]. Henan Med Res, 2023, 32(22):4048-4051. doi:10.3969/j.issn.1004-437X.2023.22.004.

组别		PLT/（×10⁹/L）						PCT/%
组别		治疗前		治疗后		t		治疗前		治疗后	t
对照组		20.52±4.48		57.93±7.35		65.497^＊		0.08±0.02		0.17±0.05	21.482^＊
研究组		19.37±4.03		61.72±8.32		63.129^＊		0.09±0.03		0.20±0.07	19.019^＊
t		1.251		2.239^＊				1.819		2.287^＊
组别	PDW/%						MPV/fL
组别	治疗前		治疗后		t		治疗前		治疗后			t
对照组	32.62±6.38		20.08±5.34		25.080^＊		29.58±5.62		18.88±5.13			23.712^＊
研究组	33.28±6.63		17.81±4.48		30.266^＊		30.62±6.09		16.64±4.57			29.737^＊
t	0.470		2.136^＊				0.823		2.138^＊

组别		PLT/（×10⁹/L）						PCT/%
组别		治疗前		治疗后		t		治疗前		治疗后	t
对照组		20.52±4.48		57.93±7.35		65.497^＊		0.08±0.02		0.17±0.05	21.482^＊
研究组		19.37±4.03		61.72±8.32		63.129^＊		0.09±0.03		0.20±0.07	19.019^＊
t		1.251		2.239^＊				1.819		2.287^＊
组别	PDW/%						MPV/fL
组别	治疗前		治疗后		t		治疗前		治疗后			t
对照组	32.62±6.38		20.08±5.34		25.080^＊		29.58±5.62		18.88±5.13			23.712^＊
研究组	33.28±6.63		17.81±4.48		30.266^＊		30.62±6.09		16.64±4.57			29.737^＊
t	0.470		2.136^＊				0.823		2.138^＊

组别	CD3⁺/%						CD8⁺/%
组别	治疗前		治疗后		t		治疗前		治疗后			t
对照组	43.75±5.51		48.73±5.12		11.184^＊		32.30±3.24		30.26±3.13			7.668^＊
研究组	44.32±5.24		51.31±5.83		15.010^＊		32.36±3.31		29.05±2.94			12.566^＊
t	0.492		2.180^＊				0.085		2.021^＊
组别		CD4⁺/%						CD4⁺/CD8⁺
组别		治疗前		治疗后		t		治疗前		治疗后	t
对照组		42.64±4.03		49.32±5.11		16.851^＊		1.32±0.27		1.63±0.35	11.447^＊
研究组		41.42±4.34		51.71±5.52		24.039^＊		1.28±0.25		1.78±0.31	20.724^＊
t		1.351		2.083^＊				0.713		2.104^＊

组别	CD3⁺/%						CD8⁺/%
组别	治疗前		治疗后		t		治疗前		治疗后			t
对照组	43.75±5.51		48.73±5.12		11.184^＊		32.30±3.24		30.26±3.13			7.668^＊
研究组	44.32±5.24		51.31±5.83		15.010^＊		32.36±3.31		29.05±2.94			12.566^＊
t	0.492		2.180^＊				0.085		2.021^＊
组别		CD4⁺/%						CD4⁺/CD8⁺
组别		治疗前		治疗后		t		治疗前		治疗后	t
对照组		42.64±4.03		49.32±5.11		16.851^＊		1.32±0.27		1.63±0.35	11.447^＊
研究组		41.42±4.34		51.71±5.52		24.039^＊		1.28±0.25		1.78±0.31	20.724^＊
t		1.351		2.083^＊				0.713		2.104^＊

组别	TPO/（ng/L）
组别	治疗前			治疗后		t
对照组	126.75±18.37			220.72±25.07		48.619^＊
研究组	123.32±17.24			234.11±28.82		49.359^＊
t	0.893			2.299^＊
组别		IL-11/（ng/L）
组别		治疗前	治疗后		t
对照组		1.26±0.15	1.55±0.26		14.253^＊
研究组		1.31±0.14	1.69±0.32		14.433^＊
t		1.598	2.227^＊